Table 1 The baseline demographic data in two groups
TV group (n = 18) | MV group (n = 30) | P value | |
|---|---|---|---|
Male, n (%) | 12 (66.7) | 17 (56.7) | 0.55 |
Age (years) | 54.9 ± 14.1 | 56.8 ± 13.0 | 0.64 |
Duration of MAT (months) | 3.0 (2.0, 8.25) | 9.5(2.0, 26.3) | 0.23 |
Time of MAT occurrence post-surgery | 2.5 (0.0, 90.0) | 12(0.0, 84.0) | 0.83 |
AADs prior to ablation | 1.7 ± 0.7 | 1.7 ± 0.8 | 0.87 |
Comorbidities | |||
Hypertension, n (%) | 5 (27.8) | 10 (33.3) | 0.69 |
Diabetes Mellitus, n (%) | 3(16.7) | 5(16.7) | 1.00 |
History of Stroke, n (%) | 0 | 2 (5.7) | – |
Concomitant cardiac defect, n (%) | Epstein’s anomaly 1 (5.5) PDA 1 (5.5) | CABG 4 (13.3), VSD 1(3.3) | 0.60 |
TTE measurement | |||
LAD (mm) | 48.3 ± 8.9 | 48.1 ± 5.6 | 0.91 |
LVEDD (mm) | 46.8 ± 4.8 | 49.2 ± 6.4 | 0.17 |
LVESD mm) | 32.4 ± 4.5 | 35.4 ± 7.1 | 0.12 |
Septum | 10.0 ± 1.3 | 9.6 ± 2.7 | 0.60 |
RAD | 44.8 ± 10.8 | 41.8 ± 4.4 | 0.18 |
RALD | 51.7 ± 6.6 | 50.1 ± 3.7 | 0.30 |
LVPW | 9.6 ± 1.7 | 9.0 ± 2.0 | 0.30 |
LVEF (%) | 56.4 ± 8.5 | 52.0 ± 10.7 | 0.15 |